<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00499070</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000553058</org_study_id>
    <secondary_id>EWOG-MDS-RC-06</secondary_id>
    <nct_id>NCT00499070</nct_id>
  </id_info>
  <brief_title>Assessing Immune Function in Young Patients With Cytopenia That Did Not Respond to Treatment</brief_title>
  <official_title>TCR Vbeta Repertoire and PNH Clones in Children With Refractory Cytopenia (RC). An Open Nonrandomised Multi-Center Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Freiburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Freiburg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Studying biopsy, bone marrow, and blood samples from patients with cytopenia that
      did not respond to treatment may help doctors learn more about the disease and plan the best
      treatment.

      PURPOSE: This laboratory study is assessing immune function in young patients with cytopenia
      that did not respond to treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To evaluate the value of TCR V beta repertoire analysis for the determination of
           autoimmunity in refractory cytopenia (RC).

        -  To evaluate which immunophenotypic hematopoietic subclones are associated with
           oligoclonal T-cell expansion in RC.

        -  To evaluate the presence of paroxysmal nocturnal hemoglobinuria (PNH) clones in RC.

      Secondary

        -  To compare the molecular response with the hematologic response in patients with RC
           after treatment with immunosuppressive therapy (IST).

        -  To compare the molecular response with human leukocyte histocompatability antigen (HLA)
           expression in patients with RC after treatment with IST.

      OUTLINE: This is an open-label, multicenter, nonrandomized, prospective study.

      Patients undergo biopsy, bone marrow, and blood sample collection periodically for
      immunological studies. Samples are analyzed for TCR V beta repertoire and paroxysmal
      nocturnal hemoglobinuria (PNH) clone analysis via PCR heteroduplex analysis and
      immunophenotyping of CD14, CD16 , CD55, CD59, and CD24 expression via flow cytometry.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with TCR V beta oligoclonality at diagnosis</measure>
    <time_frame>96 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunophenotype of patients with oligoclonal T-cell expansion</measure>
    <time_frame>96 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with glycophosphatidylinositol (GPI) deficient clones</measure>
    <time_frame>96 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with molecular response as compared to hematological response after IST</measure>
    <time_frame>96 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with HLA-DR15 antigen expression and molecular response as compared to number of patients with other HLA-DR antigens and molecular response</measure>
    <time_frame>96 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>96 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Failure-free survival</measure>
    <time_frame>96 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">119</enrollment>
  <condition>Dyskeratosis Congenita</condition>
  <condition>Fanconi Anemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Pearson Marrow-pancreas Syndrome</condition>
  <condition>Shwachman-diamond Syndrome</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymerase chain reaction</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>flow cytometry</intervention_name>
    <description>For analyzing GPI deficient clones full blood will be analyzed by phenotyping using flowcytometry. For that purpose CD14, CD16 and CD24 expression will be evaluated in CD45 positive cells. Erythroid cells will be evaluated for CD55 and CD59 expression searching for clear populations with a lack of GPI-linked molecules. In addition, immunophenotyping using flowcytometry will be performed to evaluate which differentiation stages of the major hematopoietic lineages in BM and PB are associated with TCRVβ repertoire skewing. Comparison between BM and PB will identify which is the optimal compartment to analyze the responsible hematopoietic clones.</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunologic technique</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy</intervention_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Bone Marrow Peripheral blood cells
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with MDS
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of refractory cytopenia (RC) including any of the following:

               -  Severe aplastic anemia (SAA)

               -  Fanconi's anemia

               -  Shwachman Diamond syndrome

               -  Dyskeratosis congenita

               -  Pearson syndrome

          -  All RC patients included in the EWOG MDS 2006 protocol irrespective of therapy

          -  Patients who have undergone hematopoietic stem cell transplantation (HSCT) may be
             enrolled on EWOG-MDS SCT RC RIC 06 or EWOG-MDS SCT MDS 06 protocol

        PATIENT CHARACTERISTICS:

          -  Not specified

        PRIOR CONCURRENT THERAPY:

          -  No prior immunosuppressive therapy for refractory cytopenia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marry M. Van Den Heuvel-Eibrink, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Erasmus MC - Sophia Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Anna Children's Hospital</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ghent University</name>
      <address>
        <city>Ghent</city>
        <zip>B-9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Motol</name>
      <address>
        <city>Prague</city>
        <zip>150 06</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arhus Universitetshospital - Skejby</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetskinderklinik - Universitaetsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>D-79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Our Lady´s Hospital for Sick Children</name>
      <address>
        <city>Dublin</city>
        <zip>12</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione I.R.C.C.S. Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus MC - Sophia Children's Hospital</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Deu</name>
      <address>
        <city>Barcelona</city>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <removed_countries>
    <country>Poland</country>
  </removed_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 10, 2007</study_first_submitted>
  <study_first_submitted_qc>July 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2007</study_first_posted>
  <last_update_submitted>January 15, 2015</last_update_submitted>
  <last_update_submitted_qc>January 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Freiburg</investigator_affiliation>
    <investigator_full_name>Charlotte Niemeyer, MD</investigator_full_name>
    <investigator_title>MD Prof. Dr. med. Niemeyer</investigator_title>
  </responsible_party>
  <keyword>refractory cytopenia with multilineage dysplasia</keyword>
  <keyword>aplastic anemia</keyword>
  <keyword>Fanconi anemia</keyword>
  <keyword>dyskeratosis congenita</keyword>
  <keyword>Shwachman-Diamond syndrome</keyword>
  <keyword>Pearson marrow-pancreas syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Fanconi Anemia</mesh_term>
    <mesh_term>Fanconi Syndrome</mesh_term>
    <mesh_term>Dyskeratosis Congenita</mesh_term>
    <mesh_term>Bone Marrow Diseases</mesh_term>
    <mesh_term>Lipomatosis</mesh_term>
    <mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
    <mesh_term>Lipid Metabolism, Inborn Errors</mesh_term>
    <mesh_term>Muscular Diseases</mesh_term>
    <mesh_term>Mitochondrial Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

